A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). - Wikidata - awgldk - TriplyDB

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).

http://www.wikidata.org/entity/Q46055629

about

Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies Modelling clinical systemic lupus erythematosus: similarities, differences and success stories Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus Failure of a systemic lupus erythematosus response index developed from clinical trial data: lessons examined and learned.Lupus pathobiology based on genomics.Autoimmunity-associated protein tyrosine phosphatase PEP negatively regulates IFN-α receptor signaling Pathways leading to an immunological disease: systemic lupus erythematosus.Extracellular Vesicles as Therapeutic Agents in Systemic Lupus Erythematosus NKG2D+CD4+ T Cells Kill Regulatory T Cells in a NKG2D-NKG2D Ligand- Dependent Manner in Systemic Lupus Erythematosus.Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE.Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus.A cytotoxic anti-IL-3Rα antibody targets key cells and cytokines implicated in systemic lupus erythematosus Drugs in early clinical development for Systemic Lupus Erythematosus.Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus Human effector B lymphocytes express ARID3a and secrete interferon alpha.Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.Lupus nephritis and B-cell targeting therapy.Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.Upcoming Therapeutic Targets in Cutaneous Lupus Erythematous.Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.Biologics for the treatment of autoimmune renal diseases.What Causes Lupus Flares?Recent advances and current state of immunotherapy in systemic lupus erythematosus.Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser.Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab.Present and future of biologic drugs in primary Sjögren's syndrome.Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials.Advances in the treatment of cutaneous lupus erythematosus.Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus.Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options.Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus.Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE.Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics.Systemic lupus erythematosus biomarkers: the challenging quest.Systemic lupus erythematosus diagnosis and management.It hasn't gone away: the problem of glucocorticoid use in lupus remains.Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design.

P2860

Q26746697-2093F3A2-6C62-4F98-BCB6-F0C822E19C19 Q26786973-6E1490B6-7848-4967-8716-DB75F13C9E18 Q28074217-C742E612-C6F7-4C8C-9165-2A6BEDF86F96 Q28088753-68ECB0D2-308C-4FFA-BFF4-8439B4A0A60A Q31160251-CEC67BF2-AC8E-4860-8781-D8F8ACFC2643 Q33364409-E0CF731E-3156-48BD-B0E3-6EF1A65397BF Q33423646-C63384B6-FC4C-430A-81F4-069802264D20 Q33620555-9263E8C3-EA6D-4BC0-BC33-31CD7FF9557F Q33624336-0C46A533-3108-4476-B16E-413A4D5E9517 Q33682274-464E15EB-14F0-4CC5-933D-4FAA0C8BC7C9 Q35233621-A3730C6C-5D8B-4EA3-8DE6-31B6CA901B8D Q37121715-00270C5A-EC52-4053-888A-E53E738AA571 Q37277281-6D76D0B6-094E-4B6A-A828-29DE7BDE05C4 Q37324772-815CFF99-626A-4B67-81D6-72AF7D20DD9F Q37633396-7B10A540-90B3-486D-A2E2-3AC130664469 Q37633408-A725B146-9DA5-4F6C-ABE6-BC461E0417C4 Q38291271-AA613F60-BC3F-420D-A189-966138E47DA3 Q38605480-581108C9-E55A-4E90-A66F-429C68CDB5B6 Q38643755-96DEA4E8-F376-4BF3-B083-D00AF2B71B5F Q38690844-E2F7D7A8-1243-45B1-B72C-DA51FAEBE21D Q38708002-351C79B7-F1A8-4445-9B54-D13D51E81651 Q38729214-5ADF7025-A68A-465B-997E-F1CD0F2050E3 Q38747383-375C0CB0-3BAA-48CF-AD50-63EEECD4F357 Q38763327-61CAE92A-1C9A-48A6-90DD-9A3445AA917D Q38764104-4342F2D9-FA6B-4AE4-8F9D-2FE267FC9096 Q38794663-FF43E08B-AF90-4A08-85D4-395B78CAB13A Q38799791-BF51B015-A5DB-4570-A788-0A9894160758 Q38813080-D66C9FFA-5DD9-4812-A3B4-F4F61AB3B4AC Q38822415-38E3E200-1158-4881-A79D-862D67B28CBF Q38840646-009424A3-8283-4DA9-BA93-0B1119A3AEC9 Q38851093-2CFAC0DC-8B6D-44A9-B725-2BF261B352FB Q38857518-7901B340-2655-47FD-9663-A05940541039 Q38867891-A85133AB-A501-44FD-90F6-F0F3E9CD8609 Q38888137-BACD6DE0-51F7-4CBB-8AB2-45022538D77E Q38979169-0CF33498-A897-4F8C-AC18-882B27FDDC55 Q38988559-42B4F3CF-D7A8-4B76-822F-52BC84998350 Q39053118-5BDBE11F-D7F3-4080-B576-407925BC5612 Q39053129-FB2AE12C-2A8C-4F7D-AAFD-59729B54FEBA Q39053147-5EF8469A-70FE-4C5D-9A92-485B257C49A9 Q39088664-7B3CB3B8-E55F-416A-AD61-7161C517856F

P2860

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).

http://www.wikidata.org/entity/Q46055629

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

A Phase II study of the effica ...... ic lupus erythematosus (ROSE).

@en

A Phase II study of the efficacy and safety of rontalizumab

@nl

type

label

A Phase II study of the effica ...... ic lupus erythematosus (ROSE).

@en

A Phase II study of the efficacy and safety of rontalizumab

@nl

prefLabel

A Phase II study of the effica ...... ic lupus erythematosus (ROSE).

@en

A Phase II study of the efficacy and safety of rontalizumab

@nl

P1433

Q46055629-19B9EA31-7A6A-49BD-8145-86B5F01AE9C5

P1476

Q46055629-09139404-A4AB-4C37-AB78-2C8B81CE3100

P2093

Q46055629-46D63E4B-D718-4C2A-8704-7EBDAF71ACB6

Q46055629-50BB4353-524A-4A4B-A967-942E63F69615

Q46055629-599C1D6F-8D77-4DEB-AEF3-C85197CBFE6B

Q46055629-5F0980C4-F6E4-4D4C-B73B-2534FBF55C8C

Q46055629-75416BA1-0739-4E31-97C2-26C74A6FEAB0

Q46055629-8715048D-36EE-4D31-8ED8-B07FF6D4FA6E

Q46055629-AB325494-9242-45B9-9929-6E9684FAE208

Q46055629-E1995CD2-6057-4E8A-AFDD-D668EBD4A12D

P2860

Q46055629-0E529F0D-99DB-4045-B4F0-327DFE9EE870

Q46055629-106B814A-8C38-4215-BA95-58F7E4E14F9F

Q46055629-12D7B9C0-E8B6-47EB-853E-7EACAAF3177F

Q46055629-3392814D-6FB0-4796-89CA-73201F83A0EE

Q46055629-3AEFBE95-DBC1-44CE-B0B8-83BDFED6D9DF

Q46055629-4210CE34-CAFB-4BD1-AAE3-0B9AFF366D3C

Q46055629-46DEBFCD-2609-4D9A-9E30-B2EDCBC8738D

Q46055629-4A43C4EB-2A85-4242-ADD3-0E2E27705FB3

Q46055629-51A4F932-5264-4AE2-8057-A6E8ADB45781

Q46055629-574DB934-8728-4C17-B112-13DDFBC439AB

P304

Q46055629-C15634A2-6AD2-4973-9817-F60989A46FFC

P31

Q46055629-E952319F-1DDE-4A29-844E-9EA998B08520

P356

Q46055629-840E322A-6F5B-495C-AD4C-00D4CEBB9BA1

P407

Q46055629-2DD311F5-08F6-4CC2-AC2D-74569642969E

P433

Q46055629-A1BF076F-6720-462C-A332-36D4038D5887

P478

Q46055629-EA8E7B70-8F02-4F16-B4D7-4977F26B1749

P577

Q46055629-D6ECBACE-6271-4441-9C85-174E65307A39

P5875

Q46055629-1BB78857-FF22-4CBE-8785-1F61305BC287

P698

Q46055629-9391303C-E162-4254-80B2-ECA3ED55B27A

P921

Q46055629-2798266A-C026-414E-8B1B-3C118AD98EAD

P356

ANNRHEUMDIS-2014-206090

P1433

Annals of the Rheumatic Diseases

P1476

A Phase II study of the effica ...... ic lupus erythematosus (ROSE).

@en

P2093

Jacqueline M McBride

http://www.w3.org/2001/XMLSchema#string

Joan T Merrill

http://www.w3.org/2001/XMLSchema#string

John C Davis

http://www.w3.org/2001/XMLSchema#string

Kenneth C Kalunian

http://www.w3.org/2001/XMLSchema#string

Michael J Townsend

http://www.w3.org/2001/XMLSchema#string

Romeo Maciuca

http://www.w3.org/2001/XMLSchema#string

William P Kennedy

http://www.w3.org/2001/XMLSchema#string

Xiaohui Wei

http://www.w3.org/2001/XMLSchema#string

P2860

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus

The 1982 revised criteria for the classification of systemic lupus erythematosus

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort.

Numerical scoring for the BILAG-2004 index

Recent insights into the genetic basis of systemic lupus erythematosus

P304

196-202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2014-206090

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277782737

http://www.w3.org/2001/XMLSchema#string

P698

26038091

http://www.w3.org/2001/XMLSchema#string

P921